The American Society of Clinical Oncology 2026 annual meeting showcased how, across tumour types, new cancer therapies are achieving deeper responses, extending survival and increasingly moving ...

Roche's chief medical officer, Levi Garraway. Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new ...

For the first time, children in the US as young as two with the blood disorders sickle cell disease and beta thalassaemia are ...

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new agreement to develop drugs for ...

As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...

The agency, consultancy, and investor segments saw a wave of senior-level appointments across April and May, as organisations ...

Orca Bio has become a commercial-stage company with the FDA approval of Tregzi, a cell-based immunotherapy designed to ...

Pfizer's Ibrance has become the first CDK4/6 inhibitor to be approved by the FDA for a challenging subtype of breast cancer ...

Sanofi is preparing to expand the use of its Pompe therapy Nexviazyme, currently approved only for late-onset cases of the ...

Once hailed as the “gold standard” for cancer management, though, MDTs are now under strain. Over the years, the number of referrals have gone up drastically and meeting times have increased to up to ...

Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq, in what is being seen as a test of the appetite among investors for earlier-stage drug developers. The ...

This week's collection of venture capital financings in the biotech arena includes rounds for Celea, Beeline, Flare, Lycia, and Telum. PureTech's Celea eyes phase 3 for IPF drug a ...